reports
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Fu...
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million.Preliminary unaudited ...
Soleno Therapeutics Announces Publication of Results from Pivotal Stud...
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Withdraw...
Dollar General Corp: 2 directors
Two Directors at Dollar General Corp sold/sold after exercising options 9,782 shares at between 133.355USD and 134.890USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by al...
Oxbridge / SurancePlus and Alphaledger Announce Partnership to Bring R...
Oxbridge / SurancePlus and Alphaledger Announce Partnership to Bring RWA High-Yield Tokenized Reinsurance to the Solana Ecosystem GRAND CAYMAN, Cayman Islands, Dec. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced a strategic partnership with , a leading developer of RWA (Real World Assets) -native tokenized securities infrastructure. The partnership, formally unveiled at , marks first official entry into the ecosystem, bringing one of the world’...
Soleno Therapeutics Announces the Passing of Board Member William G. H...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibited pragmatism and a...
Oxbridge / SurancePlus to Attend Abu Dhabi Finance Week (ADFW) and Sol...
Oxbridge / SurancePlus to Attend Abu Dhabi Finance Week (ADFW) and Solana Breakpoint 2025 GRAND CAYMAN, Cayman Islands, Dec. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced that the Company will be attending a series of premier global events in Abu Dhabi next week - bringing together the world’s largest financial institutions, capital allocators, and blockchain innovators. These engagements support mission to expand institutional access to tokeniz...
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NYEvercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gab...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Health...
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Healthcare Conference on Thursday, December 4, 2025, at 9:00 AM Eastern Time. A and replay of the presentation will be available in the Investors section on the Company’s we...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Shar...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock. “These actions demonstrate our confidence in our commer...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q...
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q3 2025 Results GRAND CAYMAN, Cayman Islands, Nov. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its results for the three and nine months ended September 30, 2025. SurancePlus 2025–2026 Tokenized Reinsurance Update continues to demonstrate strong performance across its 2025–2026 tokenized reinsurance offerings. The Balanced Yield Token (EtaCat Re), which targeted a 20% annual...
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-8...
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Thera...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and P...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 wa...
Oxbridge / SurancePlus Provide Performance Update on 2025/26 Tokenized...
Oxbridge / SurancePlus Provide Performance Update on 2025/26 Tokenized Reinsurance Offerings GRAND CAYMAN, Cayman Islands, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced an update on the performance of its 2025/2026 tokenized reinsurance securities. – Balanced Yield Token: Targeted 20% - Tracking 25% – High Yield Token: Targeted 42% - Is on track to achieve its targeted return , CEO of , commented, “These results underscore the Company’s c...
Oxbridge / SurancePlus to Speak at Uncorrelated Cayman 2025
Oxbridge / SurancePlus to Speak at Uncorrelated Cayman 2025 GRAND CAYMAN, Cayman Islands, Oct. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced that Chairman and CEO will speak on the panel “Tokenization and Stablecoins: Building the Bridge Between Traditional Finance and On-Chain Markets” at Uncorrelated Cayman 2025, taking place November 9-11, 2025 at Hotel Indigo Grand Cayman. Tokenization and stablecoins are transforming how assets are issued,...
Soleno Therapeutics to Participate in Upcoming November Conferences
Soleno Therapeutics to Participate in Upcoming November Conferences REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Stifel 2025 Healthcare ConferencePresentation Date: Wednesday, November 1...
Oxbridge Announces 2025 Third Quarter Results on November 6, 2025
Oxbridge Announces 2025 Third Quarter Results on November 6, 2025 GRAND CAYMAN, Cayman Islands, Oct. 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its plans to hold a conference call on Thursday November 6, 2025 at 4:30 p.m. Eastern time to discuss results for the third quarter ending September 30, 2025. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge’s management will host the conference...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on ...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.